UK drugmaker AstraZeneca\u00a0has been exploring a deal to combine with US rival\u00a0Bristol\u00a0Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter.<\/p>\n
The deal could create one of the world\u2019s biggest pharmaceutical groups with a combined value of nearly $400 billion.<\/p>\n
Astra Zeneca has been talking with Bristol Myers Squibb about a possible combination, the Financial Times reported. Bloomberg via Getty Images<\/p>\n
The companies have held talks on a potential tie-up in recent months, the report said, adding that a deal could materialize soon, but could also be delayed or fall apart.<\/p>\n
Reuters could not immediately verify the report. AstraZeneca declined to comment, while\u00a0Bristol\u00a0Myers did not immediately respond to a Reuters request for comment outside regular business hours.<\/p>\n
Last year, AstraZeneca unveiled\u00a0plans\u00a0for a direct US listing, aiming to capitalize on stronger valuations in the US market while remaining listed in London.<\/p>\n
The company\u2019s\u00a0share price\u00a0has more than quadrupled during Pascal Soriot\u2019s 14-year tenure as CEO, soaring above the wider FTSE 100 index and main British rival GSK.<\/p>\n
A combination of AstraZeneca and Bristol Myers Squibb would be valued at $400 billion, the report said. dpa\/picture alliance via Getty Images<\/p>\n
The Discovery Centre R&D facility at AstraZeneca\u2019s headquarters in Cambridge, England. Bloomberg via Getty Images<\/p>\n
Second-quarter\u00a0results\u00a0last week showed strong demand for cancer and rare disease drugs continues to drive growth. Cancer treatments accounted for about $25 billion in 2025 sales, nearly half of the total, followed by cardiovascular, renal and metabolism treatments worth about $12 billion.<\/p>\n
The report of the potential deal comes about a dozen years after AstraZeneca\u00a0fended off a takeover\u00a0attempt by larger US rival Pfizer.<\/p>\n","protected":false},"excerpt":{"rendered":"UK drugmaker AstraZeneca\u00a0has been exploring a deal to combine with US rival\u00a0Bristol\u00a0Myers Squibb, the Financial Times reported on…\n","protected":false},"author":2,"featured_media":96006,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,633,23712,2029,6],"class_list":["post-96005","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-business","tag-mergers-acquisitions","tag-pharmaceuticals","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117029158542912550","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/96005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=96005"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/96005\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/96006"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=96005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=96005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=96005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}